Index. Note: Page numbers of article titles are in boldface type.

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, described, DSM-V changes related to, panic disorder and, Amitriptyline for anxiety in pediatric medical setting, 650 Amygdala attentional modulation of, in PTSD neuroimaging of, 581 Antidepressant(s) tricyclic for anxiety in pediatric medical setting, 650 for SAD, 532 Anxiety age-appropriate vs. pathologic anxiety, 644 in children parental psychopathology and, See also Parental psychopathology, child anxiety related to described, parental as risk factor for anxiety disorders, pathologic vs. age-appropriate anxiety, 644 in pediatric medical setting, age-appropriate vs. pathologic, 644 assessment of, FSSs, 647 physical disease and, psychosomatic considerations, somatopsychic considerations, 645 treatment of, pharmacotherapy in, psychotherapy in, prevalence of variance in estimates of, Child Adolesc Psychiatric Clin N Am 21 (2012) childpsych.theclinics.com /12/$ see front matter 2012 Elsevier Inc. All rights reserved.

2 692 Index school-based treatment of, See also School-based anxiety, treatment of treatment of FCBT in studies on, Anxiety disorders. See also specific disorders awareness of, 480 CBT for, See also Cognitive behavioral therapy (CBT), for anxiety disorders clinical practice in implications for, correlates of, described, developmental epidemiology of, diagnostic criteria for, diagnostic status of stability of, 465 familiarity of, 482, 485, 487, 490 fear-based neuroimaging studies of, described, for GAD, implications for research and clinical practice, for OCD, for SAD, for social phobia, frequently occurring, genetics of, See also Genetic(s), of pediatric anxiety disorders heterotypic continuity of, 466 mixed treatment of psychopharmacologic, natural course of, predictors of, 465 neural substrates of, onset of, 463 outcome of, prevalence of, , cumulative, 461 psychopathological complications of development of, remission of, risk factors for, demographics, 467 environmental, familial aggregation, parental anxiety and depression, personality, temperament, stability of, transmission mechanisms in, 468

3 Index 693 treatment of attentional retraining in, implications for research, psychopharmacologic, See also specific disorders and drugs for GAD, guidelines for, implications for research and clinical practice, for mixed anxiety disorders, for panic disorder, for SAD, 532 for social phobia, in young children described, PCIT for, See also Parent child interaction therapy (PCIT), for anxiety disorders, in young children Association analysis in genetic identification in anxiety disorders, 480 Atomoxetine for mixed anxiety disorders, 534 Attentional retraining for anxiety disorders, B Baltimore Child Anxiety Treatment Study in the Schools (BCATSS) in school-based anxiety management, 657, BCATSS. See Baltimore Child Anxiety Treatment Study in the Schools (BCATSS) Behavior(s) disruptive parent child interaction therapy for, Benzodiazepines for anxiety in pediatric medical setting, 650 for GAD, for separation anxiety disorder, 532 Brain plasticity of PTSD and, 583 BTB domain containing 3 (BTBD3) gene, Buspirone for GAD, 529 C CALM Program for anxiety disorders in young children, Candidate gene studies of anxiety disorders, of OCD, of panic disorder, 486 of PTSD, CBT. See Cognitive behavioral therapy (CBT)

4 694 Index Child PTSD Interview, 579 Child PTSD Symptom Scale (CPSS), 579 Childhood Trauma Questionnaire (CTQ), 580 Child parent psychotherapy (CPP) for PTSD, 585 Children s PTSD Inventory (CPTSDI), 579 Citalopram for anxiety in pediatric medical setting, 650 for social phobia, 532 Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA), 579 Cognitive Behavioral Intervention for Trauma in Schools (CBITS) for PTSD, 584 in school-based anxiety management, 658, Cognitive behavioral therapy (CBT) for anxiety disorders, See also specific disorders GAD, methods overview of, SAD, 544 social phobia, 548, for selective mutism, sertraline plus for mixed anxiety disorders, 534 COMT in genetic identification of panic disorder, 486 Contactin-associated protein-like 2 in anxiety disorders, 491 Cool Kids Program: School Version in school-based anxiety management, Cortisol in PTSD, 580 D Demographics as risk factor for anxiety disorders, 467 Depression parental as risk factor for anxiety disorders, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) changes to panic attack, panic disorder, and agoraphobia, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) on selective mutism, on social phobia, Disruptive behaviors parent child interaction therapy for, DSM-IV-TR. See Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) DSM-V. See Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)

5 Index 695 E Emotion(s) regulation of CBT for GAD in, 546 Environment as risk factor for anxiety disorders, Epigenetics of PTSD, 489 Eye movement desensitization and reprocessing (EMDR) for PTSD, 584 F Familial aggregation as risk factor for anxiety disorders, Family-based cognitive-behavioral therapy (FCBT) for child anxiety studies on, Fas apoptotic inhibitory molecule 2 (FAIM2) gene, 485 FCBT. See Family-based cognitive-behavioral therapy (FCBT) Fear circuitry of development of, development of, 502 normative, neurocircuitry in, Fear-based anxiety disorders neuroimaging studies of, See also specific disorders and Anxiety disorders, fear-based, neuroimaging studies of Fluoxetine for GAD, for mixed anxiety disorders, for social phobia, 530 Fluvoxamine for mixed anxiety disorders, 533 FSSs. See Functional somatic symptoms (FSSs) Functional magnetic resonance imaging (fmri) for GAD, for OCD, Functional somatic symptoms (FSSs) anxiety and, 647 G GAD. See Generalized anxiety disorder (GAD) Gene environment interactions in PTSD, 488 Generalized anxiety disorder (GAD) CBT for, emotion regulation, 546 imaginal exposures, mindfulness,

6 696 Index clinical presentations of, 545 defined, 545 diagnosis of, 545 familiarity of, 490 genetics of, candidate gene studies in, genomewide association studies in, 491 linkage studies in, 490 implications for research, neuroimaging studies of, for at-risk children, fmri, psychopharmacologic treatment of, Genetic(s) of pediatric anxiety disorders, See also specific disorders, e.g., Obsessive-compulsive disorder (OCD), genetics of association analysis in, 480 candidate gene studies in, , 486, GAD, genomewide association studies in, , 487, genotyping advances in, 481 identifying risk genes in, implications for clinical practice and research, 492 linkage analysis in, 480, , , OCD, panic disorder, prevalence of, 482, 485, 487, PTSD, SAD, social phobia, specific phobia, Genomewide association studies in anxiety disorders, 491 of OCD, of panic disorder, 487 of PTSD, H Hippocampus in PTSD neuroimaging of, 582 I Imaginal exposures CBT for GAD in, Intergenerational Trauma Treatment Model (ITTM) for PTSD, 585 International OCD Foundation (IOCDF) Genetics Collaborative,

7 Index 697 L Linkage analysis in anxiety disorders, 490 described, 480 in OCD, in panic disorder, in PTSD, M Magnetic resonance imaging (MRI) functional for OCD, for GAD fmri, structural MRI, 509 structural for OCD, 515 Medical setting anxiety in, See also Anxiety, in pediatric medical setting Mindfulness CBT for GAD in, Mirtazapine for anxiety in pediatric medical setting, 650 Monoamine(s) in PTSD, Multi-Modal Trauma Treatment (MMTT) Protocol for PTSD, 584 Mutism selective. See Selective mutism N Neural signaling systems in PTSD, Neural substrates of childhood anxiety disorders, Neuroimmunoendocrine systems in PTSD, 488 Neuropeptide S receptor gene in genetic identification of panic disorder, 486 Neurotrophic tyrosine kinase receptor type 2 in anxiety disorders, 491 NIMH Obsessive-Compulsive Genetic Association Study (OCGAS), 485 O Obsessive-compulsive disorder (OCD) comorbidity of, 557 described, familiarity of,

8 698 Index features of, 557 genetics of, candidate gene studies in, genomewide association studies in, linkage studies in, prevalence of, 482 transmission mode in, 482 neuroimaging studies of, fmri, phenomenology of, 556, 558 prevalence of, 481, 556 subtypes of, 482 tic disorders and clinical controversies, 566 implications for clinical practice, implications for research, 565 phenomenologic overlap, distinctions, and comorbidity, 557, treatment of, OCD. See Obsessive-compulsive disorder (OCD) P Panic attack DSM-V related to, physiologic symptoms of, 595 Panic disorder, agoraphobia and, biological factors in, 596 described, diagnostic criteria for, 594 DSM-V changes related to, familiarity of, 485 genetics of, candidate gene studies in, 486 genomewide association studies in, linkage studies in, prevalence of, 485 treatment of, implications for research and clinical practice, 600 pharmacotherapy in, psychopharmacologic, psychosocial, Parental psychopathology child anxiety related to, , described, implications for clinical practice, implications for research, literature on, 682 treatment outcomes, in treatment-seeking families, 670

9 Index 699 treatment of effects on child anxiety, 671 assessment of top-down studies in, Parent child interaction therapy (PCIT) for anxiety disorders in young children, CALM Program, described, empirical support, 615 implications for research and clinical practice, 616 modification of, 610 SAD, for disruptive behavior problems, for PTSD, 585 Paroxetine for social phobia, 530 PCIT. See Parent child interaction therapy (PCIT) Personality as risk factor for anxiety disorders, Phobia(s) social. See Social phobia specific. See Specific phobia Physical disease anxiety and, Posttraumatic stress disorder (PTSD), assessment of, behavioral studies in, neurobiological studies in, neuroimaging in, single-event vs. multiple-event trauma, brain plasticity and, 583 classification of, 574 limitations of, 578 cortisol in, 580 diagnostic criteria for proposed changes for, familiarity of, gene environment interactions in, 488 genetics of, candidate gene studies in, genomewide association studies in, 489 linkage studies in, 489 prevalence of, neurobiology in, treatment of implications for research and clinical practice, 586 psychotherapeutic interventions in, PRACTICE in PTSD management,

10 700 Index Prefrontal cortex in PTSD neuroimaging of, 582 Psychopathology parental child anxiety related to, , See also Parental psychopathology, child anxiety related to Psychosocial interventions for selective mutism, for social phobia, PTSD. See Posttraumatic stress disorder (PTSD) S SAD. See Separation anxiety disorder (SAD) SASS. See Skills for Academic and Social Success (SASS) School-based anxiety treatment of, advantages of, 656 BCATSS in, 657, CBITS in, 658, Cool Kids Program: School Version in, implications for research and practice, SASS in, 659, School refusal, described, treatment of, implications for research and clinical practice, literature on, Selective mutism age of onset of, 623 assessment of, causes of, comorbidity of, course of, DSM-IV-TR diagnostic criteria for, epidemiology of, 623 social phobia and, treatment of, CBT in group, individual, emerging therapies in, implications for research and clinical practice, 633 pharmacotherapy in, psychosocial, social effectiveness therapy in, 630 SSRIs in, Selective serotonin reuptake inhibitors (SSRIs) for anxiety in pediatric medical setting, for selective mutism, for social phobia, Separation anxiety disorder (SAD) CBT for,

11 Index 701 clinical presentations of, defined, 543 diagnosis of, 543 familiarity of, 490 genetics of, candidate gene studies in, genomewide association studies in, 491 linkage studies in, 490 implications for research, neuroimaging studies of, PCIT for modification of, psychopharmacologic treatment of, 532 Serotonin transporter gene in anxiety disorders, Sertraline for GAD, 528 plus CBT for mixed anxiety disorders, 534 for social phobia, 530, 532 Skills for Academic and Social Success (SASS) in school-based anxiety management, 659, Social effectiveness therapy for selective mutism, 630 for social phobia, 630 Social phobia age of onset of, 623 assessment of, causes of, CBT for, 548 clinical presentations of, 548 comorbidity of, course of, defined, diagnosis of, DSM-IV-TR diagnostic criteria for, epidemiology of, 623 familiarity of, 490 genetics of, candidate gene studies in, genomewide association studies in, 491 linkage studies in, 490 implications for research, 548 neuroimaging studies of, selective mutism and, treatment of, CBT in group, individual, 629 emerging therapies in, implications for research and clinical practice, 633 pharmacotherapy in, psychopharmacologic,

12 702 Index psychosocial, social effectiveness therapy in, 630 Specific phobia familiarity of, 490 genetics of, candidate gene studies in, genomewide association studies in, 491 linkage studies in, 490 SSRIs. See Selective serotonin reuptake inhibitors (SSRIs) Stanford Cue-Centered Therapy (CCT) for PTSD, 585 Structural magnetic resonance imaging for GAD, 509 for OCD, 515 T Temperament as risk factor for anxiety disorders, Tic disorders described, OCD and clinical controversies, 566 implications for clinical practice, implications for research, 565 phenomenologic overlap, distinctions, and comorbidity, 557, phenomenology of, prevalence of, treatment of, Tourette syndrome phenomenology of, treatment of, , Trauma single-event vs. multiple-event PTSD due to, Trauma-focused cognitive behavioral therapy (TF-CBT) for PTSD, Trauma Symptom Checklist for Children (TSCC), Trauma systems therapy (TST) for PTSD, 585 Tricyclic antidepressants (TCAs) for anxiety in pediatric medical setting, 650 for SAD, 532 U UCLA PTSD Reaction Index for DSM-IV (PTSD-RI), 579 V Venlafaxine for GAD, 529 Venlafaxine ER for social phobia, 530